Brokerages Set Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Target Price at $25.00

Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) have received an average rating of “Moderate Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $24.50.

Several analysts recently weighed in on the company. Guggenheim upped their price objective on Phathom Pharmaceuticals from $20.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, February 27th. Stifel Nicolaus set a $28.00 price objective on Phathom Pharmaceuticals in a research report on Thursday, February 26th. Barclays upgraded Phathom Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $16.00 to $18.00 in a research report on Friday, March 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Tuesday, April 21st.

Phathom Pharmaceuticals Stock Performance

Shares of PHAT stock opened at $9.82 on Wednesday. The stock’s fifty day moving average price is $11.57 and its two-hundred day moving average price is $12.96. The company has a market cap of $783.24 million, a PE ratio of -4.63 and a beta of 0.50. Phathom Pharmaceuticals has a fifty-two week low of $7.61 and a fifty-two week high of $18.31.

Institutional Investors Weigh In On Phathom Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd bought a new position in shares of Phathom Pharmaceuticals in the 4th quarter valued at $27,000. Jones Financial Companies Lllp lifted its stake in shares of Phathom Pharmaceuticals by 442.6% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,523 shares of the company’s stock valued at $30,000 after acquiring an additional 2,058 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Phathom Pharmaceuticals in the 2nd quarter valued at $30,000. Summit Securities Group LLC bought a new position in shares of Phathom Pharmaceuticals in the 1st quarter valued at $34,000. Finally, Kestra Advisory Services LLC bought a new position in shares of Phathom Pharmaceuticals in the 4th quarter valued at $38,000. 99.01% of the stock is owned by institutional investors.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.